Lipid Therapeutics GmbH was founded in early 2008 in Heidelberg. The mission is to develop novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a delayed release of Phosphatidylcholine, for the treatment of Ulcerative colitis based on the preclinical and clinical work conducted by Prof. Stremmel from the University Hospital Heidelberg.

Managing Director

Gerhard Keilhauer, PhD, is a biologist and chemist and holds a PhD in neurobiology from the University of  Heidelberg.
During his professional career Dr. Keilhauer has gained broad experience in big pharma as well as in the biotech industry. Most recently he was as chief development officer of 4SC AG for almost 7 years responsible for preclinical and clinical development. Before, he spent almost 16 years with BASF Pharma/Knoll AG in leading positions in R&D both in Europe as well as in the US.

Chairman of the Board

Engelbert C.Tjeenk Willink received his Medical Degree from Erasmus University Rotterdam. During his medical studies he also spent a few years doing research at the University of  Florida. After completing his medical studies, he led a Phase I Clinical Contract Research Center for four years before moving to the position of Medical Director at Boehringer Ingelheim in the Netherlands. Subsequently, during his almost 20 years stay at the company he led various organizations within the Boehringer Ingelheim. From Corporate Health Economics & Outcomes Research to Global Marketing, but also heading Marketing & Sales in Canada and Country Management in Mexico. His last four years at the company he was a member of the Board of Managing Directors, responsible for Marketing & Sales Human Pharmaceuticals, an organization with in excess of € 10 billion sales. During his time in executive positions within the Boehringer Ingelheim organization, the company consistently grew above the market and climbed in the ranking of the pharmaceutical industry.

Board Member

Christoph Boehringer graduated from the University of Munich with a degree in Mechanical Engineering after completing his training in banking and finance at the private banking establishment Merck Finck& Co. Upon finishing his studies, he deepened his knowledge in the areas of finance, investment and M&A through working at the banking house JP Morgan. He worked for JP Morgan in New York and London.
Mr. Boehringer is founding Partner of Mediatum, an executive recruitment company specializing in the life science industries and he is one of the founding partners of CD-Venture GmbH, as well as of Binder & Associates GmbH.
Since 1997 he is also Member of the Shareholders’ Committee of Boehringer Ingelheim, a body comparable to a board of directors of a business quoted on the stock exchange.
Apart from various seats on the boards of directors and consultation at start-up businesses, Mr. Boehringer is a business angel.


Dr. Jan Adams is a Managing Director with EMBL Ventures, focusing on opportunities in the life science and medical device sector. Prior to joining EMBL Ventures Dr. Adams was a postdoctoral Fellow of the Ernst Schering Research Foundation at the University of Granada, Spain, where he did work on stem cells. Before that he was a Fellow of the Boehringer Ingelheim Research Foundation, conducting work on molecular transport mechanisms at the Wellcome CRC in Cambridge, UK. Dr. Adams holds a M.S. in Biochemistry & Molecular Biology from Tübingen University, Germany and completed a PhD in Genetics at the University of Cambridge, UK.


Dr. Alexander Asam has more than 20 years of experience in the life sciences and private equity businesses currently being partner at HBM Partners AG one of the global leaders leaders in healthcare-focused investing. In this function he is member of various Boards in Europe and the US. He was former managing director and partner of Deutsche Venture Capital (DVC) and held various positions at LION Bioscience, among others as member of the IPO Core Team (dual listing Germany and USA). Before he held various positions at the pharmaceutical companies Hoechst AG and Aventis S.A. (now: Sanofi) with increasing responsibility. He holds an MBA degree from ASTON Business School, Birmingham and a MSc and PhD in chemistry from University of Heidelberg.